+44 (0)1865 595230 nac.contact@lgcgroup.com
0 Items
Select Page

New SARS-CoV-2 Neutralisation Assay Development Kits

To support the characterisation of SARS-CoV-2 variants, The Native Antigen Company now offers an extended range of variant RBD-ACE2 Neutralisation Assay Development Kits, including:

• Delta Variant
• Kerala Variant
• South African Variant
• Brazilian Variant
• UK Variant
• Wild-Type

With all the key reagents required to measure Spike-antibody binding, these easy-to-use, cell-free kits can be used to identify and qualitatively assess the ability of antibodies to neutralise variant RBD-ACE2 interactions. For more information, please see the information below:

Delta Variant (B.1.617.2)

Our SARS-CoV-2 Delta Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.617.2 RBD (L452R, T478). In-house data shows that different SARS-CoV-2-positive patient sera is able to variably neutralise binding:

SARS-CoV-2 Neutralisation Assay Development Kit (Indian)

NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #2 is between 50% and 60% and is therefore positive for the presence of neutralizing antibodies. SARS-CoV-2 serum samples #1 and #3 are >60%, indicating no neutralizing capacity.

Kerala Variant (Kappa/B.1.617.1)

Our SARS-CoV-2 Kerala Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.617.1 RBD (E484Q, L452R). In-house data shows that different SARS-CoV-2-positive patient sera is able to variably neutralise binding:

SARS-CoV-2 Neutralisation Assay Development Kit (Indian)

NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum samples #1 and #2 are <50% and therefore positive for the presence of neutralizing antibodies. Serum sample #3 is 60%, indicating no neutralizing capacity.

South African Variant (Beta/B.1.351/501Y.V2)

Our SARS-CoV-2 South African Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.351 RBD (K417N, E484K, N501Y). In-house data shows that SARS-CoV-2-positive patient sera is able to neutralise binding:

SARS-CoV-2 Neutralisation Assay Development Kit (South Africa)

NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #1 is >60%, indicating that neutralizing antibodies are absent.

Brazilian Variant (Gamma/B.1.1.28)

Our SARS-CoV-2 Brazilian Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.1.28 RBD (K417T, E484K, N501Y). In-house data shows that SARS-CoV-2-positive patient sera is able to neutralise binding:

SARS-CoV-2 Neutralisation Assay Development Kit (Brazil)

NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #1 is >60%, indicating no neutralizing capacity.

UK Variant (Alpha/B.1.1.7)

Our SARS-CoV-2 UK Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the N501Y RBD. In-house data shows that SARS-CoV-2-positive patient sera is able to neutralise binding:

SARS-CoV-2 Neutralisation Assay Development Kit (UK)

NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #1 is >50% but <60%, indicating moderate neutralizing capacity.

Wild-Type (Wuhan-Hu-1)

Our SARS-CoV-2 Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to wild-type SARS-CoV-2. In-house data shows that different SARS-CoV-2-positive patient sera is able to variably neutralise binding:

RBD-ACE2 Kit Data [Landing Page]

NTRL assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum samples #1, #2 and #3 are < 50% and considered strongly positive indicating SARS-CoV-2 neutralizing antibody is present in these samples. Samples #4, #5 and #6 are derived from SARS patient sera, and show binding of >50%, indicating moderate or negative neutralizing capacity.

See Our Full SARS-CoV-2 Range

In addition to our neutralisation kits, we offer an extensive range of reagents to support research into the coronaviruses, including antigens, antibodies, receptors enzymes and custom development services. For more information, click the tiles below:

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...